Sponsor
GlaxoSmithKline Australia
86 PBAC submissions on file, active 2005–2025. 72% have been recommended.
Submissions
86
2005 → 2025
Win rate
72 %
62 recommended of 86 bucketable
Drugs
52 · 37 listed
unique molecules submitted
PBS spend captured
—
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Respiratory 30 Oncology 19 Vaccines 16 Haematology 5 Immunology 5 Infectious disease 2 Rheumatology 2 Urology 2 Diabetes 2 Pain 1
Activity by year 2005 (1) · 2006 (5) · 2007 (7) · 2009 (3) · 2010 (4) · 2011 (2) · 2012 (1) · 2013 (4) · 2014 (13) · 2015 (3) · 2016 (5) · 2017 (3) · 2018 (5) · 2019 (6) · 2020 (5) · 2021 (4) · 2022 (3) · 2023 (7) · 2024 (3) · 2025 (2)
Rejection patterns
Across 23 Not recommended decisions on file.
2× uncertain clinical benefit1× Clinical impact for patients switching for reasons other than treatment failure is unclear1× cost-effectiveness and financial risk to government are unknown1× administrative difficulty in managing patients who failed a drug during initiation and wish to restart it1× concern that allowing switching could grow the market and increase overall TRA useOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.